To report the results of a survey conducted among retina specialists in the Asia-Pacific region on real-life practice patterns in the management of vitreoretinal diseases.
T he subspecialty of vitreoretinal ophthalmology continues to evolve. In the past 2 decades there have been sweeping technological changes in both diagnostics and therapeutics. Some of these include the change from limited-field retinal photography to wide-angle nonmydriatic retinal photography, spectral-domain optical coherence tomography (OCT) to OCT angiography (OCT-A), laser photocoagulation as primary therapy in diabetic macular edema (DME) to intravitreal injection of anti-vascular endothelial growth factor (VEGF), and 20-gauge (G) to 27G vitrectomy. These evolving technologies do not necessarily translate into clinical practice, at least not immediately. Further, there are variations in regional and global practices.
The American Society of Retina Specialists collects information about the practice patterns of United States-based ophthalmologists and has recently extended to international ophthalmologists through the annual Preferences and Trends (PAT) survey. [1] [2] [3] The 2017 survey included responses of 1077 members and 38 societies across the globe. This included over 750 ophthalmologists from the United States with the remaining from other countries, and only 7.1% of responses were from the Asia-Pacific region. Considering the fact that more than 60% of the world's population live in the Asia-Pacific region, the responses from this region in the 2017 PAT survey do not possibly document real-world vitreoretinal practice (similar response rates of 8.5% and 7.1% were found in 2015 and 2016, respectively). Therefore, a survey of the retina specialists practicing in the AsiaPacific region would potentially yield important, unique, and relevant regional information.
METHODS
The Asia-Pacific Vitreo-retina Society conducted online Technology and Trend (TAT) surveys to study the technology and practice trends among retina specialists in the Asia-Pacific region in 2016 and 2017. The questionnaire was designed by retina specialists (J.C., T.D., D.L., O.W.K., Y.S.Y., J.E., R.K.) practicing medical and surgical retina in the Asia-Pacific region. The survey assessed the routine clinical practice patterns of retina specialists across the Asia-Pacific region. Questions were limited to the management of common retinal diseases. Exemption from ethics approval has been granted by the institutional ethics committee of Hyderabad Eye Research Foundation. The survey included ophthalmologists practicing medical and/or surgical retina, who registered with their country-specific vitreoretina societies or interest groups. A link was sent to 1400 retinal physicians across the Asia-Pacific region by email, which directed to a web-based questionnaire page (Google forms or Survey Monkey) with secure confidential access. The e-mail provided a basic introduction for the respondents explaining the study details, definitions, instructions, and contact details of the investigators. This questionnaire study was conducted under full participant anonymity. Respondents could skip a question and proceed to the next one. They could not modify their responses once submitted and each of them was allowed only one submission. The 2016 and 2017 surveys included a 36-and 40-item questionnaire, respectively. Of the questions, 30 were common in the 2 surveys and such repetition provided a trend over 1 year; respective 6 and 10 questions were included exclusively in the 2016 and 2017 surveys.
The responses were compiled in an Excel spreadsheet and charts. The analysis gives an overview of practice trends among retinal physicians across the Asia-Pacific region in recent 2 years.
RESULTS
Of 1400 retinal specialists who received the email broadcast in 2016 and 2017, 539 and 200 completed the survey giving a response rate of 38.5% and 14.3%, respectively.
In the 2-year surveys, responses were mainly from India (44.6% and 43.0%, respectively), South Korea (9.5% and 13.5%), and Taiwan (7.5% in 2016) and Thailand (20.0% in 2017) ( Table  1) .
In both surveys, a majority of retina specialists (83.9-85.5%) practiced combined medical and surgical retina, followed by exclusive medical retina (11.7-12.1%) and exclusive surgical retina (2.8-4.0%) (Appendix).
MEDICAL RETINA Dry Age-Related Macular Degeneration
In treating dry age-related macular degeneration (AMD), 47.3% of respondents "always prescribed" according to the AgeRelated Eye Disease Study (AREDS) formulation for AREDS category 3 or 4, 44.2% did it "sometimes", and 7.5% "never prescribed".
Wet Age-Related Macular Degeneration
In 2016, the preferred practice was intravitreal anti-VEGF therapy. Ranibizumab (35-41%) and bevacizumab (36-48%) was the most preferred, followed by aflibercept (16-21%). The "treat and extend" method was the most preferred anti-VEGF injection protocol (43-47%), followed by "as needed" (26-30%). Combination therapy of anti-VEGF with photodynamic therapy was the most widely practiced option (46-51%) in nonresponding AMD. Other preferred options were increasing frequency through a biweekly schedule (5-8%) or by doubling the dose of anti-VEGF drug (8%), along with triple therapy of verteporfin photodynamic therapy (vPDT), steroids, and anti-VEGF (5-9%). Regarding switching, almost half of respondents (43-50%) considered that a nonresponse to wet AMD treated with ranibizumab/bevacizumab showed favorable response to aflibercept only in less than one fourth of cases. On the other hand, a small proportion of respondents (6-8%) considered that the response rate was over 75% in cases with aflibercept.
Polypoidal Choroidal Vasculopathy
In treating polypoidal choroidal vasculopathy (PCV), 59.0% of practitioners used vPDT in combination with anti-VEGF (36.0% deferred vPDT and 23.0% performed baseline vPDT); 39.5% did not use vPDT and preferred anti-VEGF monotherapy only. The first-line anti-VEGF drug was aflibercept (52.5%). The treatment goal in PCV was one of the following: absence of fluid on OCT (41.5%), regression of polyp (26.0%), or improved vision and regression of polyp (21.0%).
Myopic Choroidal Neovascular Membrane
A majority of respondents (63-73%) used exudative signs on OCT as the criteria to treat myopic choroidal neovascular membrane (CNVM); almost one-fifth (11-18%) treated the disorder based on a change in vision and approximately 15% would treat if exudative signs appeared on fundus fluorescein angiography (FFA).
Diabetic Macular Edema
A total of 74.1% of respondents used the recent international classification system of DME based on center-involving or noncenter-involving DME. 4 The first-line therapy in centerinvolving DME in a phakic eye was anti-VEGF (78-87% of respondents), followed by a combination of anti-VEGF and lasers (12-18%) and implantable dexamethasone (1-2%). In a pseudophakic eye with DME, 18.5% preferred implantable dexamethasone, and 71.0% favored anti-VEGF therapy. In nonresponsive eyes, approximately 58% switched to another anti-VEGF after 2 to 3 injections, 22% after 4 to 5 injections, 11% to 15% after 5 to 6 injections, and 5% to 9% after more than 6 injections. The most common switch was from anti-VEGF to dexamethasone implants. 
Proliferative Diabetic Retinopathy
In treating proliferative diabetic retinopathy (PDR), half of respondents (47-53%) did not use anti-VEGF monotherapy suggested by the DRCR protocol S, 5 12% preferred using it, 19% to 31% used it sometimes only, and 12% to 16% would defer this decision to a future time.
Macular Edema Secondary to Branch Retinal Vein Occlusion
For macular edema secondary to branch retinal vein occlusion (BRVO) of 1-month duration with good vision (20/40), a majority of respondents (84%) opted for anti-VEGF, followed by observation (10-11%), implantable dexamethasone (3-5%) and modified grid laser (1-2%). For recalcitrant edema due to BRVO that showed no response to 6 anti-VEGF injections, 42% to 53% would switch to implantable dexamethasone, 8% to 13% would consider sector scatter photocoagulation, and 38% to 39% would perform both.
Macular Edema After Central Retinal Vein Occlusion
For phakic eyes with macular edema after central retinal vein occlusion, 93.9% preferred treatment with anti-VEGF, and only 3.2% preferred a dexamethasone implant as the first-line of treatment.
Chronic Central Serous Chorioretinopathy
In treating chronic central serous chorioretinopathy, some respondents (30-52%) preferred vPDT as the first choice. Other protocols included micropulse laser (7-9%), oral medications (7-9%), and thermal laser (20-24%). With regard to vPDT protocols, one-third (29-35%) preferred half fluence, others (0.2-21%) preferred half dose, and 2.0% preferred standard TAP (Treatment of AMD with Photodynamic Therapy) protocol. 6 When asked specifically about the use of oral medications, 42-43% had never used it, one-third (30-33%) used it in less than 25% of cases, and 10-13% used it as often as in more than 75% of cases.
Topical Antibiotic Prophylaxis in Anti-VEGF Therapy
Many respondents prescribed topical antibiotic after an intravitreal injection (38-45%) and both before and after injection (30-39%); some (15-18%) had never used it, and only a small proportion (6-8%) used it in selected patients. The mode of procurement of bevacizumab was as follows: one-fourth (25-27%) of respondents practiced multiple pricks and stored the drug in a refrigerator for 2 to 3 weeks, some (26-29%) aliquoted at the institute, some (11-18%) pooled patients and discarded the vial immediately after use, and some (13-17%) acquired it from the compounding pharmacy. With regard to the location of performing intravitreal injections, approximately half (48-56%) performed injections in the main operating room, one-fourth (24-28%) in a minor operating room, and one-fifth (15-20%) in the office.
SURGICAL RETINA Vitreomacular Interface Disorders
A majority of respondents would observe a focal vitreomacular traction (37-45%), would perform vitrectomy (29-37%). One-tenth (11-12%) would prefer injecting ocriplasmin (Jetrea, Thrombogenics US or Alcon/Novartis EU), a recombinant human serine protease plasmin, but lack of access was the limitation. A small proportion of respondents (2-5%) would inject air to induce posterior vitreous detachment.
Internal Limiting Membrane Peeling
In an epiretinal membrane (ERM) removal surgery, a majority of respondents (42-43%) performed internal limiting membrane (ILM) peeling quite often (75-100%) but a certain proportion (4-8%) never did it.
Dye for Internal Limiting Membrane Peeling
When performing ILM peeling, over half of respondents (57-60%) used brilliant blue G dye (triphenylmethane), followed by indocyanine green (polymethine dye) (15-16%), triamcinolone (6-8%), and trypan blue (azo dye) (5-7%). Some did not use any dye (2-3%).
Macular Hole Surgery
A total of 27.5% of surgeons performed ILM peeling and inverted ILM flap technique only if the base diameter was larger than 400 μm; 25.5% performed for a larger base diameter of more than 800 μm, 23.5% performed for failed cases only, and 11.5% performed as a primary procedure in all cases. After a macular hole repair, 50.5% prescribed a face-down position up to 1 week, and 22.5% recommended 1 to 3 days only. Only 13.5% prescribed for more than 1 week.
Timing for Traumatic Macular Hole Surgery
Almost one-third of surgeons (27-29%) would wait for 2 to 3 months before operating on a traumatic macular hole, but for more surgeons (34-40%), the decision to operate was based on the macular hole size/posterior vitreous detachment. Some respondents (4-8%) would never operate.
Macular Schisis
A similar proportion of respondents preferred vitrectomy with or without tamponade for macular schisis (46-47%) and observation (40-43%). Only 1% would consider macular buckle.
ADVANCED TECHNOLOGIES Vitrectomy Systems
In 2016, 60.6% of respondents used 23G vitrectomy, 25.1% used 25G, and approximately 2% each use 27G and 20G systems. In the survey of both 2016 and 2017, a majority (62-68%) admitted to reusing the disposable instruments and some (23-38%) did not reuse them.
Ultra-Widefield Imaging
To perform ultra-widefield imaging, a similar proportion of respondents used an Optos camera (Optos panoramic P200Tx, Dunfermline, UK) (23-26%) and Heidelberg Spectralis (Spectralis HRA+OCT system, Heidelberg, Germany) (20-24%). Around half (50-55%) did not use a wide-angle imaging modality.
Indocyanine Green Angiography
With regard to indocyanine green angiography (ICGA), 52% used it only for 2 to 3 patients per month and 8% to 9% used it as frequently as 7 to 9 patients per week.
Optical Coherence Tomography
A majority of practitioners (86%) had access to spectraldomain OCT in their clinic; 9.5% had swept-source OCT, whereas 4.2% were still using a time-domain OCT.
Choroidal Imaging
Almost one-third (29-31%) of respondents had never used choroidal imaging, 40% to 43% used it less often (around 1-25% of cases), and only 4% to 5% used it quite often (75-100% of cases).
Optical Coherence Tomography Angiography
Of the respondents, 58.3% did not have access to OCT-A, 3.9% had the facility but never used it, and 36.7% used OCT-A. More than one-third (37−39%) of practitioners believed that use of OCT-A could not replace FFA/ICGA, whereas another onethird (28−31%) believed that OCT-A had successfully replaced the need for invasive modality in up to 25% of patients.
Intraoperative Optical Coherence Tomography
Regarding intraoperative OCT, 87.5% had never used it, 7.5% had used it and believed it to be helpful/useful, and 3.5% did not find it a useful tool after a demonstration.
Head Up/3D Operating Microscope System
A total of 78.0% of respondents had never used a 3-dimensional visualization system for vitrectomy, 9.0% had used it and found it helpful, and 3.0% of users did not find it useful.
Teleophthalmology
A majority of respondents (72-75%) had no access to teleophthalmology yet. For diabetic retinopathy screening, 76.5% used table-top fundus cameras, and 5.0% and 4.5% used smartphone-based and handheld fundus cameras, respectively.
Retinopathy of Prematurity Screening
When asked about retinopathy of prematurity screening, most respondents (58-61%) responded affirmatively, one-third (29-31%) did not do screening, and 9.0% said it was done by a pediatric ophthalmologist at their center. Table 2 shows the comparison of our survey results in 2016 with the United States and global responses of the PAT survey in the same year.
DISCUSSION
Medical practice evolves with improved understanding of disease pathophysiology, newer treatment concepts, and the precision of diagnostic tools. Hence, a periodic assessment of tools, techniques, and trends is essential. In recent years the PAT survey by the American Society of Retina Specialists is such an attempt. This captures the practice patterns in the retina subspecialty in the United States, and in the recent past it has expanded to the international retina specialists community. Considering the small response from the retinal specialists in the Asia-Pacific region in the PAT survey (7% to 8% in the years 2015-2017) the current survey of retina specialists practicing in the Asia-Pacific region is of higher significance.
The Asia-Pacific region is very diverse, occupying 22% of the world's land mass that is home to 60% of the global population. This region hosts the world's most populous country (China, 1.4 billion people) and the least populous country (Brunei, 0.4 million people). The gross domestic product also varies widely, with China at the top and Tonga at the bottom. In this diverse economy, it is important to capture the trend of both technique and technology in broad and diverse health care systems. This survey was designed to capture both types of information in the vitreoretinal practice in the region.
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The average economy of the Asia-Pacific region would suggest more frequent use of off-label bevacizumab in wet AMD. However, this was not the case. The fact that ranibizumab was preferred by 41% of retina specialists in 2016 would suggest a greater influence of scientific evidence in the published literature. [8] [9] [10] An alternative possibility is the nonavailability of compounding pharmacies in most countries in the Asia-Pacific region. Incidentally, ranibizumab is used in wet AMD more often in Canada than in the United States. 11 The influence of published evidence on practice is demonstrated in the management choice for PCV. The condition of PCV is typically considered a more Asian disease and randomized clinical trials have shown the superiority of both the combination of vPDT and ranibizumab or aflibercept monotherapy.
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Myopia and consequent development of CNVM is an important eye health issue in Asia. 15 Asia-Pacific retina specialists tend to follow the guidelines of the RADIANCE study, the randomized clinical trial for the management of CNVM secondary to myopia. 16 It provided 2 strategies of retreatment: one based on visual acuity (treatment is initiated in the event of reduction in visual acuity compared with the previous 2 visits) and the other based on disease activity (treatment is initiated with the evidence of fluid on OCT or leakage on FFA/ICGA). In our survey, about two-thirds of Asia-Pacific retina specialists rely on the OCT criteria for activity, and only 15% use FFA for treatment decisions, despite the fact that FFA is a more sensitive indicator of activity in myopic CNVM. This may be due to the ease of performing a noninvasive test such as OCT.
Anti-VEGF remains the first-line therapy in center-involving DME in both phakic and pseudophakic eyes. Almost 20% would consider implantable dexamethasone as the primary treatment for center-involving DME in pseudophakic eyes. The switch of treatment in anti-VEGF nonresponders was to implantable dexamethasone. This switch was relatively earlier in Asia-Pacific retina specialists (58% after 2-3 anti-VEGF injections in the current survey) compared with retina specialists from the United States (37.5% after 4-5 injections in the PAT survey) ( Table 2) .
A marked variance was identified in the administration of prophylactic antibiotics in anti-VEGF injections. This response was similar to that made by international retina specialists outside the United States documented in the PAT survey (Table 2 ). In the absence of a randomized controlled trial, several retrospective studies have not documented additional benefit of perioperative prophylactic antibiotics. 17, 18 We suspect that this practice stems from uncertainty of the general sterile environment or the hygienic practice of patients. These fears must be translating into the practice of administering anti-VEGF injections in an operating or specially designed procedure room as distinct from the outpatient office setting.
The DRCR protocol S has shown the benefits of anti-VEGF injection in eyes with PDR with or without concurrent DME. 5 However, the downside was the cost of care and compliance. In this survey, about half of respondents do not give anti-VEGF therapy for PDR, 12% do, and 16% are ready to use it in future. In the 2017 PAT survey, 71.6% of physicians in the United States and 51.6% globally considered panretinal photocoagulation a better modality than anti-VEGF monotherapy for PDR; this may be related to concerns of noncompliance and the seemingly inconclusive results of protocol S. Thus, photocoagulation continues to be the preferred mode of therapy for PDR in Asia, the United States, and the world, at least for the present time.
The current study showed that the frequency of ILM peeling for ERM in the Asia-Pacific region is less than that in the United States (51% vs 63%) and brilliant blue G is the preferred dye (57%) in contrast to indocyanine in the United States (69%). 1, 3 It is worth noting that brilliant blue G is not yet approved in the United States.
A majority (88%) of respondents in the Asia-Pacific region have never used intraoperative OCT technology, which is almost the same as 82% of respondents from the United States and 83% of global respondents. Although 34% of respondents in the United States and 43% globally believe it to be useful, 22% and 16% respectively, believe it to be of no particular value, and 25% in both the United States and the world believe that it could become useful when technology improves.
The majority of clinicians in the Asia-Pacific region do not have access to advanced technologies like wide-angle imaging systems (Optos/Heidelberg), autofluorescence, ICGA, choroidal imaging systems, swept-source OCT, and OCT-A, which have become the standard of care.
Our study has many limitations. The response rate was only 38.5% in 2016 and 14.3% in 2017%, and there was a very poor response from the most populous country, China. Hence, we suspect these results may at best present a trend rather than a true representation of practice patterns across the Asia-Pacific region. As the response to the PAT survey gradually increased from 35% in 2015 to 60% in 2017, we also expect an improvement in response rate in the coming years. As this is a survey, it cannot be a true reflection of evidence-based practices. Nonetheless, this is the first attempt to demonstrate practice patterns across the Asia-Pacific region through a survey. It represents the impact of different disease profiles, economies, and health insurance coverage on clinical practice. Surveys performed over years would provide insight into changing trends with upcoming technology and evolving treatment strategies. Better response rate and uniform distribution of responses will improve the validity of real-life data in practice patterns. Such data could be useful for establishing health policies and standards for funding agencies. 
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